Tumor Immunology And Immunotherapy

A comprehensive account of cancer immunity and immunotherapy, examining recent results, current areas of interest and the specific issues that are affecting the research and development of vaccines. It provides insight into how these problems may be overcome as viewed by leaders in the field.

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO

The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.

Tumor Immunology and Immunotherapy - Integrated Methods Part B, Volume 636 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Chapters in this update include Quantification methods of Transforming Growth Factor beta (TGF??) activity in the setting of cancer immunotherapy, Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses, Tracking and interrogating tissue-resident and recruited microglia in brain tumors, Metabolomics and lipidomics of the tumor microenvironment, Monitoring abscopal responses to radiation in mice, and much more. Provides an array of authors who are authorities in the field Presents comprehensiveness coverage of the topics Includes a broad level of detail and in-depth coverage

Tumor Immunology and Immunotherapy - Integrated Methods Part B, Volume 636 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Chapters in this update include Quantification methods of Transforming Growth Factor beta (TGF?ß) activity in the setting of cancer immunotherapy, Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses, Tracking and interrogating tissue-resident and recruited microglia in brain tumors, Metabolomics and lipidomics of the tumor microenvironment, Monitoring abscopal responses to radiation in mice, and much more. Provides an array of authors who are authorities in the field Presents comprehensiveness coverage of the topics Includes a broad level of detail and in-depth coverage

Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.

This book explains the immunology of organ-specific malignancies and discusses novel immunotherapy strategies for their treatment. Since the first, very successful edition of the book was published in 2015, a number of entirely new chapters have been included. The range of cancers considered has accordingly been extended, with coverage of the latest immunotherapy approaches for cancers in different organs. In addition, the original chapters have been updated to document the latest advances in immunotherapy for pediatric solid tumors, hematologic malignancies, gastrointestinal tumors, bone tumors, central nervous tumors, lung cancer, genitourinary tract tumors, and breast cancer, among others. The book is published as part of the three-volume Springer series Cancer Immunology, which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Other volumes in the series address the translational medicine context and bench to bedside immunotherapy. Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors will be of special value to clinical immunologists, hematologists, and oncologists.

Tumor Immunology and Immunotherapy Integrated Methods - Part A, Volume 635 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Specific chapters to this release include Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry, High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers, Multiplex assay by IHC for melanoma tumor microenvironment evaluation, Characterization of the tumor immune microenvironment by multispectral image analysis of multiplex immunofluorescence images, Phenotyping of immune cells in situ using multispectral imaging quantification, and much more. Authored by leaders in the field of enzymology Provides a comprehensiveness level of discussion on the field Presents a highly specialized group of topics that delve deep into new updates and future prospects